Moertel Criticizes Janssen Over Levamisole Price, Delivers Final Report On Intergroup Adjuvant Trial
In Brief: Seffrin’s ACS Appointment Is Official; Liotta Selected As NIH; Strategic Plan Meetings
Other ASCO Plenary Papers: Long Awaited Chemotherapy Results
Congress Okays NIH Reauthorization, Allows NCI $472 Mil. More
Gallo Inquiry Complete; NCAB’s AIDS Committee Plans Q&A Session
NCAB Decides To End IGs, Review total Research Support, And Consider P01 Limitation
Trending Stories
- Franco Muggia, former head of CTEP and NYU cancer center, dies at 85
- House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M
House joins Senate in rejecting Trump’s proposed 40% NIH cuts - Bhattacharya fields NCAB’s questions about funding, political involvement in grant review, DEI, animal testing
- Lowy: Forward-funding policy forced NCI to drastically reduce RPG awards funded for FY25, 10% of NCI staff has been lost
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - Robert A. Winn on his new vision to train cancer center leaders: “I had a big bold idea and an ‘Aha!’ moment.”